CytoDyn Inc. Quarterly report [Sections 13 or 15(d)]

Quarterly report [Sections 13 or 15(d)]

(Loss) Income per Share (Tables)

(Loss) Income per Share (Tables)

9 Months Ended

Feb. 28, 2025

(Loss) Income per Share

Schedule of reconciliation of the numerators and denominators of basic and diluted net (loss) income per share


		Three months ended						Nine months ended
(in thousands, except per share amounts)		February 28, 2025			February 29, 2024			February 28, 2025			February 29, 2024
Numerator:
Net (loss) income		$	(4,758)		$	(11,920)		$	9,701		$	(33,054)
Less: Accrued preferred stock dividends			(365)			(369)			(1,106)			(1,110)
Net (loss) income applicable to common stockholders		$	(5,123)		$	(12,289)		$	8,595		$	(34,164)
Denominator:
Basic weighted average common shares outstanding			1,228,259			982,209			1,194,561			954,814
Effect of dilutive securities:
Warrant exercises			—			—			30,352			—
Option exercises			—			—			625			—
Diluted weighted average common shares outstanding			1,228,259			982,209			1,225,538			954,814

Basic (loss) income per share		$	(0.00)		$	(0.01)		$	0.01		$	(0.04)
Diluted (loss) income per share		$	(0.00)		$	(0.01)		$	0.01		$	(0.04)

Schedule of securities excluded from computation of earnings per share


	Three and nine months ended
(in thousands)	February 28, 2025		February 29, 2024
Stock options, and warrants	231,027		315,808
Convertible notes	12,000		12,000
Convertible preferred stock	39,265		36,298